PHARMARON's stock surged 5.09% during Tuesday's intraday trading session, following the announcement of several positive corporate actions.
The company's board has proposed to increase its registered capital from RMB 1.778 billion to RMB 1.837 billion, reflecting recent share placements and vesting of restricted shares. This capital increase typically signals growth plans and expansion initiatives that investors view favorably.
Additionally, PHARMARON announced a proposed final cash dividend of RMB2 for every 10 shares for the financial year ended December 2025, returning value to shareholders. The company also completed a management transition with the appointment of an experienced new company secretary, further strengthening its corporate governance structure.
Comments